KPTI
HEALTHCAREKaryopharm Therapeutics Inc
$9.02-0.39 (-4.14%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KPTI Today?
No stock-specific AI insight has been generated for KPTI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.65$10.99
$9.02
Fundamentals
Market Cap$200M
P/E Ratio—
EPS$-17.93
Dividend Yield—
Dividend / Share—
ROE-8.9%
Profit Margin-1.3%
Debt / Equity—
Trading
Volume180K
Avg Volume (10D)—
Shares Outstanding22.6M
KPTI News
20 articles- Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026Yahoo Finance·May 7, 2026
- Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual MeetingYahoo Finance·Apr 21, 2026
- RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term PerformanceYahoo Finance·Apr 17, 2026
- Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?Yahoo Finance·Mar 27, 2026
- KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study DataYahoo Finance·Mar 25, 2026
- Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?Yahoo Finance·Mar 25, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Mar 24, 2026
- Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in MyelofibrosisMarketbeat·Mar 24, 2026
- Karyopharm Therapeutics' Blood Cancer Therapy Meets a Key Goal in Phase 3 Study, Plans $30 Million Private PlacementYahoo Finance·Mar 24, 2026
- Karyopharm Announces $30 Million Private Placement with RA CapitalYahoo Finance·Mar 24, 2026
- Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionYahoo Finance·Mar 24, 2026
- Karyopharm myeloma drug yields mixed data in myelofibrosis trialBiopharmadive·Mar 24, 2026
- How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth ExpectationsYahoo Finance·Mar 22, 2026
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 2, 2026
- Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special MeetingMarketbeat·Feb 24, 2026
- Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to TradeYahoo Finance·Feb 18, 2026
- Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual ReportYahoo Finance·Feb 15, 2026
- Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ...Yahoo Finance·Feb 12, 2026
- Karyopharm Therapeutics Q4 Earnings Call HighlightsMarketbeat·Feb 12, 2026
- Karyopharm Therapeutics Inc. Q4 2025 Earnings Call SummaryMoby·Feb 12, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$9.41
Day High$0.00
Day Low$0.00
52 Week High$10.99
52 Week Low$3.65
52-Week Range
$3.65$10.99
$9.02
Fundamentals
Market Cap$200M
P/E Ratio—
EPS$-17.93
Dividend Yield—
Dividend / Share—
ROE-8.9%
Profit Margin-1.3%
Debt / Equity—
Trading
Volume180K
Avg Volume (10D)—
Shares Outstanding22.6M
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—